cl 1318641





CertBSE

Via Fax & Mail: (202) 777-1030 Mr. Brian Johnson, Branch Chief Securities and Exchange Commission 100 F Street, N.E. Washington, DC 20549 RECD S.E.C.

JUL 2 0 2006

1086

July 20, 2006

1-32954

RE: SEC Certification

Dear Mr. Johnson:

We submit herewith, in duplicate, a Certification of the Boston Stock Exchange, Inc., relative to listing and permanent registration pursuant to the Commission's Rule 12dl-1 for the following security:

## Cleveland Biolabs, Inc. Common Stock – \$0.005 Par Value

As it is proposed that trading may commence as soon as possible, acceleration of registration under Rule 12d1-2 is hereby requested.

ery truly

Your acknowledgment on the duplicate of this letter would be appreciated.

Anthony K. Stankiewicz, Es Vice President, Listings

Encl.


cc: Division of Market Regulation

PROCESSED

JUL 2 7 2006

THOMSON FINANCIAL Dr. Michael Fonstein CEO & President Cleveland Biolabs, Inc. 11000 Cedar Avenue, Suite 290 Cleveland, OH 44106

Ram Padmanabhan, Esq. (312) 902-1061



## CERTIFICATE OF THE BOSTON STOCK EXCHANGE RELATIVE TO LISTING AND PERMANENT REGISTRATION -PURSUANT TO RULE X-12D1-1

Securities and Exchange Commission Washington, D.C.

The Governing Committee of the Boston Stock Exchange hereby certifies that on July 20, 2006 it received from

Cleveland Biolabs, Inc.

FILE NO. FORM 8-A

what purports to be the application for permanent registration of the following securities on this Exchange:

<u>Title of Security</u> Common Stock - \$0.005 Par Value <u>Issued</u> 6,542,637

Unissued 12,000,000

that it has received the following amendments on the dates stated: Form 8-A

July 20, 2006

The Governing Committee of the Boston Stock Exchange further certifies that it has approved the above-mentioned issued securities for listing and registration, and that it has approved the above-mentioned unissued securities for addition to the list upon notice of issuance.

nthony K Stankiewic

Vice President, Listings

July 20, 2006 Date